Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Benmelstobart with Thermal Ablation in Advanced HCC
NCT04665609Phase 3Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, benmelstobart in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
anlotinibbenmelstobart
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04665609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665609.